Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive...

Dr Thomas Martin, MD, University of California, San Francisco, USA

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma ( Dr Thomas Martin, MD, University of California, San Francisco, USA )

Investigational antibody demonstrates efficacy, safety for patients with...

Dr Thomas Martin, MD, University of California, San Francisco, USA

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study ( Dr Thomas Martin, MD, University of California, San Francisco, USA )

HIV-associated lymphoma responds well to stem cell transplantation

Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA

HIV-associated lymphoma responds well to stem cell transplantation ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to...

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )

Stem cell transplantation safe for patients with HIV-associated lymphoma

Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA

Stem cell transplantation safe for patients with HIV-associated lymphoma ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )

Carfilzomib represents potent, effective addition to standard multiple myeloma...

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Post-transplant survival boosted by brentuximab vedotin in lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Post-transplant survival boosted by brentuximab vedotin in lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma...

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Children with aggressive leukaemia experiencing remission with T cell therapy

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

Children with aggressive leukaemia experiencing remission with T cell therapy ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Overall survival update from the BREAK-3 study

Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany

Overall survival update from the BREAK-3 study ( Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany )

ecancermedicalscience editor's choice for November 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for November 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

More from ecancer